Fujifilm Kyowa Kirin Biologics, a joint venture between Fujifilm Corporation and Kyowa Hakko Kirin Co., Ltd. announced last week that it will endeavor to develop a biosimilar version of bevacizumab, an anti-VEGF humanized monoclonal antibody which has impressive therapeutic effects for cancers such as colorectal cancer and non-small cell lung cancer.
Fujifilm Kyowa Kirin Biologics is a fifty-fifty joint venture between Fujifilm and Kyowa Hakko Kirin, launched on March 27, 2012 for the development, manufacture and marketing of biosimilars. Presently the company is developing a biosimilar of the fully human anti-TNF-? monoclonal antibody, adalimumab, a drug with dramatic therapeutic effects for rheumatoid arthritis, and is proceeding with preparations to begin clinical trials in Europe in the first half of 2013.
Fujifilm Kyowa Kirin Biologics intends to develop the biosimilar version of bevacizumab as the second drug in their lineup. After introducing the production cell line already produced by Kyowa Hakko Kirin, Fujifilm Kyowa Kirin Biologics plans to start clinical trials in 2014.
Source: Fujifilm Kyowa Kirin Biologics press release